|1.||Poordad, Fred: 13 articles (05/2014 - 03/2011)|
|2.||Brass, Clifford A: 13 articles (05/2014 - 08/2010)|
|3.||Bronowicki, Jean-Pierre: 12 articles (09/2015 - 03/2011)|
|4.||Albrecht, Janice K: 12 articles (05/2014 - 08/2010)|
|5.||Pedicone, Lisa D: 11 articles (05/2014 - 08/2010)|
|6.||Sulkowski, Mark S: 10 articles (05/2014 - 03/2011)|
|7.||Zeuzem, Stefan: 10 articles (11/2013 - 04/2007)|
|8.||Hézode, Christophe: 9 articles (09/2015 - 01/2012)|
|9.||Gordon, Stuart C: 9 articles (09/2015 - 08/2010)|
|10.||Jacobson, Ira M: 9 articles (08/2014 - 08/2010)|
06/01/2015 - "Boceprevir is no longer widely used in the US or EU due to the introduction of second-generation treatments for HCV infection. "
06/01/2015 - "Boceprevir (BOC) is a directly-acting antiviral agent for the treatment of hepatitis C virus genotype 1 (HCV-1) infection. "
01/01/2015 - "The durability of sustained virologic response (SVR) following boceprevir-based therapy in patients with hepatitis C virus (HCV) infection has not been reported. "
02/01/2014 - "How to optimize current therapy of HCV genotype 1 infection with boceprevir."
11/01/2013 - "Boceprevir was the first direct acting agent developed for the treatment of hepatitis C virus infection. "
|2.||Chronic Hepatitis C
02/01/2013 - "This review examines the current treatment paradigm of boceprevir-based treatment of chronic hepatitis C, examining treatment paradigms, predictors of response, futility rules, as well as preliminary results from studies examining boceprevir efficacy in additional populations. "
03/15/2015 - "A 55-year-old woman was started on boceprevir (800 mg orally thrice daily) during week 5 of triple therapy for chronic hepatitis C. "
01/01/2015 - "Boceprevir in genotype 1 chronic hepatitis C: first experiences in Serbia."
01/01/2015 - "Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C."
10/01/2014 - "In untreated genotype 1b chronic hepatitis C patients, the cost-effectiveness of boceprevir-based triple therapy widely ranges according to different profiles of sustained virological response predictors, allowing optimization and personalization of triple therapy."
03/01/2013 - "Boceprevir represents a new treatment option for hepatitis C (HCV)-infected patients, including those with HCV/human immunodeficiency virus coinfection; however, little is known about pharmacokinetic interactions between boceprevir and antiretroviral drugs. "
01/01/2013 - "The boceprevir-based regimens used in the SPRINT-2 trial were projected to substantially reduce the lifetime incidence of liver complications and increase the QALYs in treatment-naive patients with hepatitis C genotype 1. It was also demonstrated that boceprevir-based regimens offer patients the possibility of experiencing great clinical benefit with a shorter duration of therapy. "
10/01/2015 - "Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease."
10/01/2014 - "Predicting the probability of experiencing clinically significant drug-drug interactions involving boceprevir-containing hepatitis C therapy among patients coinfected with hepatitis C and HIV."
08/01/2014 - "In this real-world cohort, 49% of patients stopped boceprevir-based hepatitis C therapy early, with only 20% stopping due to treatment futility. "
07/28/2015 - "Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers."
04/01/2015 - "SVR rates were 31% (95% CI: 24-40) and 50% (95% CI: 44-56) in boceprevir patients with and without cirrhosis, respectively. "
01/01/2015 - "Boceprevir in combination with P/R achieved fairly good SVR rates in patients that were"most difficult to treat"who failed on dual therapy and was effective among patients with cirrhosis."
11/28/2014 - "Boceprevir obtained high SVR response independent of previous response, RVR or baseline fibrosis or cirrhosis. "
03/01/2014 - "A real life boceprevir use in treatment-experienced HCV genotype 1 patients with advanced fibrosis."
01/01/2012 - "Anemia, the most frequent adverse event related to administration of boceprevir, occurred in about 50% of patients. "
03/31/2011 - "Anemia led to dose reductions in 13% of controls and 21% of boceprevir recipients, with discontinuations in 1% and 2%, respectively. "
02/01/2012 - "The most common adverse events with boceprevir included anemia and dysgeusia. "
05/01/2015 - "Anemia is a well-known RBV-related event in HCV therapy which is exacerbated by the addition of telaprevir and boceprevir. "
01/01/2015 - "In terms of safety, the risks of anemia and discontinuations due to AEs were lower for simeprevir compared to PR alone, telaprevir, and boceprevir. "
|3.||Protease Inhibitors (Protease Inhibitor)
|5.||Antiviral Agents (Antivirals)
|6.||N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamide
|7.||peginterferon alfa-2b (Pegintron)
|8.||Interferon-alpha (Interferon Alfa)
|9.||RNA (Ribonucleic Acid)
|3.||Transplantation (Transplant Recipients)
|5.||Highly Active Antiretroviral Therapy (HAART)